Obesity associated with increased postmenopausal invasive breast cancer risk
the ONA take:
Obesity is associated with increased risk for invasive breast cancer in postmenopausal women, a new study published online ahead of print in JAMA Oncology has shown.
For the secondary analysis, researchers sought to investigate the associations of overweight and obesity with the risk of developing postmenopausal invasive breast cancer after a long follow-up in the Women's Health Initiative studies.
Researchers analyzed data from 67,142 postmenopausal women ages 50 to 79 years. Patients were followed for a median of 13 years. During that time, 3,388 patients were diagnosed with invasive breast cancers.
Results showed that women who were overweight and obese had an increased risk for developing invasive breast cancer compared with those of normal weight. Researchers found that women with a BMI of 35.0 or higher was strongly associated with risk of developing estrogen receptor-positive and progesterone receptor-negative breast cancers.
The findings suggest that more strategies should be developed to prevent obesity in postmenopausal women.
Obesity is associated with increased risk for invasive breast cancer in postmenopausal women.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|